BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $294.000 thousand which missed the analyst consensus estimate of $500.000 thousand by 41.20 percent. This is a 3.29 percent decrease over sales of $304.000 thousand
BioLine Rx sold way less medicine than experts thought it would—about $294,000 instead of $500,000. When a company sells less than people expected, it can mean they're struggling, so investors watch to see if they'll fix it next time.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.